Human immunodeficiency virus-associated malignancies: A therapeutic update

Current HIV Research

Volumn 10, Issue 2, 2012, Pages 123-132

  Malfitano, Antonello ^a   Barbaro, Giuseppe ^b   Perretti, Alessandro ^a   Barbarini, Giorgio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biotherapy; Chemotherapy; Highly active antiretroviral therapy; Human immunodeficiency virus; Malignancies; Stem cell rescue

Indexed keywords

ACICLOVIR; BLEOMYCIN SULFATE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOSCARNET; GANCICLOVIR; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROCARBAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANEMIA; ANUS CANCER; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; CANCER RADIOTHERAPY; CARDIOTOXICITY; DEPRESSION; DIARRHEA; DRUG MEGADOSE; FATIGUE; GENITAL TRACT CANCER; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; LYMPHEDEMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYALGIA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY EFFUSION LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; VIRUS CARCINOGENESIS; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; LYMPHOMA, AIDS-RELATED; NEOPLASMS; SARCOMA, KAPOSI;

EID: 84860308004     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799937227     Document Type: Article

References (102)

1. Appleby P, Beral V, Newton R, et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virusinfected adults. J Natl Cancer Inst 2000; 92: 1823-30.
2. Malfitano A, Barbaro G, Barbarini G. Ongoing change in the treatment of HIV-associated malignancies in the HAART era. Exp Rev Clin Pharm 2009; 2: 283-93.
3. Nguyen HQ, Magaret AS, Kitahata MM, et al. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008; 22: 937-45.
4. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29: 378-87.
5. International collaboration on HIV and cancer: highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst 2000; 92: 1823-30.
6. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54.
7. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDSrelated cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999; 13: 2563-70.
8. Aboulafia DM Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998; 73: 439-43.
9. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J. Clin Oncol 2001; 19: 3848-51.
10. Bower M, Fox P, Fife K, Gill J, et al. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-11.
11. Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 2003; 17: 747-62.
12. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Hematol Oncol Clin North Am 2003; 17: 747-62.
13. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17: 17-22.
14. Gressen EL, Rosenstock JG, Xie Y, Corn BW. Palliative treatment of epidemic Kaposi's sarcoma of the feet. Am J Clin Oncol 1999; 22: 286-290.
15. Evans MD, Yassa M, Podgorsak EB, Roman TN, Schreiner LJ, Souhami L. Surface applicators for high dose rate brachytherapy in AIDS-related Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1999; 39: 769-74.
16. Bernstein ZP, Wilson BD, Oseroff AR, et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS 1999; 13: 1697-704.
17. Walmsley S, Northfeldt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22: 235-45.
18. Bodsworth NJ, Bloch M, Bower M, Donnel D, Yocum R. Phase III vehicle controlled, multicentered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001; 2: 77-87.
19. Laubenstein LJ, Krigel RL, Odajn YKCM, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984; 2: 1115-20.
20. Gill PS, Bernstein-Singer M, Espina BM, et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1992; 6: 1477-81.
21. Gill PS, Wernz J, Scadden DT, et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353-64.
22. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized Phase III clinical trial. J Clin Oncol 1998; 16: 2445-51.
23. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683-91.
24. Henry D, Cooley P, Volberding P. Final results of a Phase III randomized trial of doxil vs daunoxome in patients with AIDSrelated Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 2002; 21: 411a (Abstract 1640).
25. Gill P, Hadienberg J, Espina B, et al. Low dose paclitaxel (Taxol) every two weeks over three hours is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. Presented at: The American Society of Hematology (ASH), Thirty-Ninth Annual Meeting, Seattle, WA, USA 2-5 December (1995) (Abstract 1516).
26. Saville M, Lietzau J, Pluda J, et al. Activity of paclitaxel (Taxol) as therapy for HIV-associated Kaposi's sarcoma. Lancet 1995; 346: 26-8.
27. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a Phase II study. J Clin Oncol 2000; 18: 1550-57.
28. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602.
29. HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23: 982-89.
30. Cianfrocca M, Cooley T, Lee J, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma: a Phase I AIDS Malignancy Consortium study. J Clin Oncol 2002; 20: 153-59.
31. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi's sarcoma. Blood 2006; 107: 4650-57.
32. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23.
33. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. AIDS 1996; 10: 1101-05.
34. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173: 1477-80.
35. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-12.
36. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32: 527-33.
37. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 1996; 10: 1111-24.
38. Gill P, Levine A, Krailo M, et al. AIDS-related malignant lymphoma. Results of prospective treatment trials. J Clin Oncol 1987; 5: 1322.
39. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1641-48.
40. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23: 4430-38.
41. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 2006; 106: 1560-68.
42. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxyldoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909-15.
43. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin's lymphoma. Cancer 2001; 91: 155-63.
44. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-91.
45. Matthews GV, Bower M, Mandalia S, et al. Changed in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2002; 96: 2730-4.
46. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-8.
47. Vinodh R, Nannan P, Richard M, et al. Paclitaxel in the treatment of immunodeficiency virus-1 associated Kaposi's sarcoma-drugdrug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharm 1999; 43: 516-9.
48. Fumagalli L, Zucchetti M, Parisi I, et al. The pharmakokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharm 2000; 45: 495-501.
49. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006; 10: 3832-40.
50. Sparano JA, Wiernik PH, HU X, et al. Pilot trial of infusional cyclophosphsmide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virusassociated, non Hodgkin's lymphoma. J Clin Oncol 1996; 14: 3026-35.
51. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22: 1491-500.
52. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of an antiretroviral suspension and tumour biology. Blood 2003; 101: 4653-54.
53. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized Phase III trial of CHOP with or without rituximab in patients with HIV-associated, non Hodgkin's lymphoma. AIDS-malignancies consortium trial 010. Blood 2005; 106: 1538-43.
54. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated, non Hodgkin's lymphoma: pooled results from 3 Phase 2 trials. Blood 2005; 105: 1891-97.
55. Boue F, Gabarre J, Gisselbrect G, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated, non Hodgkin's lymphoma. J Clin Oncol 2006; 24: 4123-28.
56. Levine AM, Lee J, Kaplan L, Liebes LF, Sparano JA. Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIVassociated lymphoma: AIDS Malignancy Consortium Trial 034. J Clin Oncol 2008; 26 (Abstract 8527).
57. Levine AM. Management of AIDS-related lymphoma. Curr Opin Oncol 2008; 5: 522-8.
58. Tirelli U, Errante D, Spina M, et al. Second line chemotherapy in HIV-related non-Hodgkin's lymphoma. Cancer 1996: 77: 2127-31.
59. Bi J, Espina B, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphomas. J Acquir Defic Syndr 2001; 28: 416-21.
60. Philip T, Guglielmi C, Hagenbeck A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl J Med 1995; 333: 1540-45.
61. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857-59.
62. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10: 116-27.
63. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89, 1100-08.
64. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high risk HIV-associated lymphomas. Blood 2005; 105: 874-78.
65. Balsalobre P, Diez Martin JL, Re A, et al. Autologous stem cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 2192-98.
66. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 d32/d32 stem-cell transplantation. N Engl J Med 2009; 360: 692-98.
67. Mazhar D, Stebbing J, Lewis R, et al. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood 2006; 107: 3412-14.
68. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98: 1196-205.
69. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-99.
70. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17: 554-60.
71. Baumgartner J, Rachlin J, Beckstead J, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73: 206-11.
72. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system in AIDS. Neurology 1994; 44: 1473-79.
73. Jacomet C, Girard P, Lebrette M, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11: 1725-30.
74. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007; 12: 569-76.
75. Serraino D, Dal Maso L, La Vecchia C, Franceschi S. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002; 16: 781.
76. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
77. Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008; 111: 1380-87.
78. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
79. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-22.
80. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 1120-30.
81. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of higly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143-53.
82. Hessol N, Katz M, Liu J et al. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann Intern Med 1992; 117: 309.
83. Reynolds P, Saunders L, Layefsky M, et al. The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, 1980-1987. Am J Epidemiol 1993; 37: 19.
84. Engels EA, Pfeiffer RM, Goedert JJ, et al. HIV/AIDS Cancer Match Study: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. AIDS 2006; 20: 1645-54.
85. Righetti E, Ballon G, Ometto L, et al. Dynamics of Epstein-Barr virus in HIV-1 -subjects on highly active antiretroviral therapy. AIDS 2002; 16: 63-73.
86. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-90.
87. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV -infected patients with newly diagnosed Hodgkin's disease: a prospective multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24:444-50.
88. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47: 422-28.
89. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 2002; 100, 1984-88.
90. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14: 1562-69.
91. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33: 487-94.
92. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383-88.
93. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17: 371-75.
94. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45: 103-10.
95. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996; 15: 325-39.
96. Lavolé A, Chouaïd C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with Non-small-cell lung cancer. Lung Cancer 2009; 51: 1-11.
97. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and out come. HIV-HCC Cooperative Italian-Spanish Group. AIDS 2004; 18: 2285-93.
98. Brau N Fox RK, Xiao P, Marks K, et al. North American Liver Cancer in HIV Study Group: Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S. Canadian multicenter study. J Hepatol 2007; 47: 527-37.
99. Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14: 1657-63.
100. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Sem Liver Dis 2006; 26: 273-84.
101. Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14: 1657-63.
102. Di Benedetto F, Di Sandro S, De Ruvo N, et al. Human immunodeficiency virus and liver transplantation: our point of view. Transplant Proc 2008; 40: 1965-71.